SCM
ITCI

Silverarc Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Silverarc Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-179,085
Closed -$15M – 84
2024
Q4 		$15M Buy
179,085
+11,975
+7% +$984K 3.27% 12
2024
Q3 		$12.2M Sell
167,110
-25,235
-13% -$1.9M 2.75% 10
2024
Q2 		$13.2M Buy
192,345
+157,538
+453% +$10.9M 3.11% 10
2024
Q1 		$2.41M Sell
34,807
-45,193
-56% -$3.11M 0.67% 44
2023
Q4 		$5.73M Sell
80,000
-128,730
-62% -$7.41M 1.71% 21
2023
Q3 		$10.9M Buy
208,730
+10,007
+5% +$583K 3.3% 6
2023
Q2 		$12.6M Buy
198,723
+73,688
+59% +$4.59M 3.89% 6
2023
Q1 		$6.77M Sell
125,035
-15,331
-11% -$741K 2.79% 10
2022
Q4 		$7.43M Buy
140,366
+4,240
+3% +$212K 2.13% 16
2022
Q3 		$6.33M Sell
136,126
-177,836
-57% -$9.29M 2.14% 18
2022
Q2 		$17.9M Buy
313,962
+5,143
+2% +$292K 5.52% 2
2022
Q1 		$18.9M Buy
308,819
+113,819
+58% +$5.91M 7.82% 3
2021
Q4 		$10.2M Buy
195,000
+93,110
+91% +$3.91M 4.14% 4
2021
Q3 		$3.8M Sell
101,890
-11,368
-10% -$395K 2.15% 14
2021
Q2 		$4.62M Sell
113,258
-16,859
-13% -$623K 2.06% 15
2021
Q1 		$4.42M Sell
130,117
-69,883
-35% -$2.42M 2.41% 11
2020
Q4 		$6.36M Buy
+200,000
New +$5.26M 3.7% 3

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Silverarc Capital Management's ITCI Position: Q1 2025 in Review

Silverarc Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 179,085 shares — an estimated $15M sold.

Silverarc Capital Management first reported a position in ITCI in Q4 2020 and held it in 17 quarters. The position peaked at $18.9M in Q1 2022. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Silverarc Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Silverarc Capital Management sold 179,085 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $15M.
  • Silverarc Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 17 quarters.
  • Silverarc Capital Management's Intra-Cellular Therapies Inc. position peaked at $18.9M in Q1 2022.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Silverarc Capital Management's 13F filing for Q1 2025, filed 14 May 2025.